Ipamorelin Peptide 10mg – Protide Health USA

Ipamorelin Overview & Technical Specifications

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue associated with the ghrelin receptor, also known as the growth hormone secretagogue receptor or GHS-R1a.

Its sequence is:

Aib-His-D-2-Nal-D-Phe-Lys-NH₂

Ipamorelin contains several non-standard amino-acid residues, including:

• Aib — α-aminoisobutyric acid
• D-2-Nal — D-2-naphthylalanine
• D-Phe — D-phenylalanine

These structural features distinguish ipamorelin from endogenous ghrelin as well as from other synthetic growth hormone-releasing peptides.

Protide Health supplies ipamorelin as 10mg of 99% purity, HPLC-MS verified, third-party tested lyophilized research material in a 3mL vial.

Technical Specifications

• Product Name: Ipamorelin
• Research Code: NNC 26-0161
• Quantity: 10mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified; third-party tested
• Peptide Type: Synthetic pentapeptide growth hormone secretagogue
• Receptor Class: Ghrelin / GHS-R1a receptor agonist
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• CAS Number: 170851-70-4
• PubChem CID: 9831659
• Molecular Formula: C38H49N9O5
• Molecular Weight: approximately 711.86 g/mol
• Appearance: White to off-white lyophilized powder
• Solubility: Soluble in water
• Storage: Store sealed at ≤6°C and protected from heat, light, and moisture
• Research Use: Ghrelin-receptor, growth hormone secretagogue, endocrine, biochemical, cellular, analytical, and qualified preclinical research only

Ipamorelin Peptide Research Context

The ipamorelin peptide was developed as part of research into synthetic growth hormone secretagogues.

Its foundational pharmacology literature characterized Ipamorelin as a potent GHRP-receptor agonist capable of stimulating GH release in experimental systems.

Research areas include:

• GHS-R1a receptor pharmacology
• Pituitary GH release
• Endocrine selectivity
• Ghrelin-mimetic signaling
• Structure-activity relationships
• Pharmacokinetics
• Comparative secretagogue research

Researchers can review broader Ipamorelin and growth hormone secretagogue research indexed by PubMed for peer-reviewed literature involving GHSR signaling, GH release, pharmacokinetics, and comparative endocrine studies.

Ipamorelin & GHS-R1a Signaling

Ipamorelin is associated with the growth hormone secretagogue receptor system.

GHS-R1a is a G protein-coupled receptor that also responds to the endogenous ligand ghrelin.

Experimental receptor activation can influence pathways involving:

• Gq-associated signaling
• Phospholipase C
• Inositol phosphate signaling
• Intracellular calcium
• Pituitary somatotroph activity
• Growth hormone secretion

Although Ipamorelin acts as a ghrelin receptor agonist, it is chemically very different from endogenous ghrelin.

Ghrelin is a longer endogenous peptide containing a distinctive acyl modification, whereas ipamorelin is a compact synthetic pentapeptide.

Ipamorelin as a Selective Growth Hormone Secretagogue

One of the most frequently cited characteristics of ipamorelin is its relative endocrine selectivity.

A 1998 study compared Ipamorelin with other growth hormone-releasing peptides and reported strong GH-releasing activity while finding substantially less ACTH and cortisol stimulation under the experimental conditions.

This was notable because GHRP-2 and GHRP-6 were associated with broader pituitary hormone responses.

The authors therefore described Ipamorelin as the first GHRP-receptor agonist with GH-release selectivity resembling that of GHRH.

This finding should be interpreted within the exact models and experimental conditions studied.

It does not establish unrestricted clinical safety or therapeutic superiority.

Ipamorelin vs Ghrelin

Ghrelin and ipamorelin peptide can interact with the same receptor family, but they are not the same molecule.

Ghrelin

• Endogenous peptide hormone
• Contains 28 amino acids
• Requires an acyl modification for canonical GHSR activity
• Participates in appetite, endocrine, gastrointestinal, and metabolic signaling

Ipamorelin

• Synthetic pentapeptide
• Sequence: Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Developed as a selective growth hormone secretagogue
• Used predominantly in experimental receptor and endocrine research

Results involving endogenous ghrelin should therefore not automatically be attributed to Ipamorelin.

Pituitary Growth Hormone Research

A major experimental application for ipamorelin is pituitary GH-release research.

In vitro and animal studies have evaluated:

• Primary pituitary cells
• GH secretion
• Dose-response relationships
• Receptor specificity
• Comparison with GHRH
• Comparison with GHRP-2
• Comparison with GHRP-6

The foundational Ipamorelin research showed a measurable GH response in both in-vitro and in-vivo models.

These findings provide mechanistic context but do not establish that a Protide Health research vial should be used in humans.

Ipamorelin Pharmacokinetic Research

Human volunteer studies have also examined the pharmacokinetics and pharmacodynamics of pharmaceutical research Ipamorelin.

A 1999 study characterized concentration-time behavior and growth-hormone responses in healthy male volunteers.

The study reported:

• Dose-proportional pharmacokinetics across the tested range
• A terminal half-life of approximately two hours
• A measurable episodic GH response
• Considerable inter-individual variability in pharmacodynamic response

These findings relate specifically to the controlled study formulation, route, population, and protocol.

They should not be converted into administration instructions for the Protide Health product.

CJC 1295 Ipamorelin Search Context

The phrase cjc 1295 ipamorelin commonly refers to combining a GHRH analogue with a growth hormone secretagogue.

The compounds operate through different receptor systems.

CJC-1295-Type GHRH Analogues

These compounds are associated primarily with:

• GHRH receptor signaling
• Gs proteins
• Adenylate cyclase
• cAMP
• Pituitary somatotroph signaling

Ipamorelin

Ipamorelin is associated primarily with:

• GHS-R1a signaling
• Ghrelin-receptor pharmacology
• GHRP-like secretagogue activity

Their different receptor pathways explain why both compounds are sometimes studied within the same endocrine research framework.

However, co-use does not itself establish biological synergy.

CJC-1295 Ipamorelin vs Standalone Ipamorelin

The phrase cjc-1295 ipamorelin should not be interpreted as another name for standalone Ipamorelin.

Standalone ipamorelin contains only the pentapeptide described on this page.

A CJC-1295/Ipamorelin formulation contains at least two distinct peptides.

This difference affects:

• Chemical composition
• Receptor pathways
• Analytical characterization
• Experimental controls
• Interpretation of observed effects

Researchers should not transfer data from a CJC-1295 combination automatically to standalone Ipamorelin.

CJC Ipamorelin Research Terminology

The shorthand cjc ipamorelin generally refers to experimental co-investigation of a GHRH analogue and Ipamorelin.

This product does not contain CJC-1295.

The Protide Health vial described here contains:

Ipamorelin 10mg only

For researchers comparing related endocrine pathways, the Tesamorelin research peptide provides a separate GHRH-receptor-focused research system.

CJC-1295 + Ipamorelin Search Intent

The phrase cjc-1295 + ipamorelin usually describes a dual-peptide combination.

From an experimental perspective, combining receptor systems may complicate interpretation because observed outcomes could arise from:

• GHRH receptor activation
• GHS-R1a activation
• Combined signaling
• Model-specific interaction
• Timing differences
• Receptor-expression differences

Appropriate controls are therefore necessary when comparing combination formulations with standalone ipamorelin peptide.

Ipamorelin Dosage Searches

The phrase ipamorelin dosage concerns human administration.

Protide Health does not provide human dosage instructions.

The 10mg quantity identifies the total amount of laboratory research material in the vial.

It is not a recommended human dose.

No instructions are provided for:

• Human injection
• Daily dosing
• Weekly dosing
• Body-weight calculations
• Treatment cycles
• Timing around exercise
• Reconstitution for administration
• Combination protocols

Published human pharmacokinetic studies used defined research protocols and regulated experimental material.

Those study conditions should not be converted into self-administration guidance.

Ipamorelin Side Effects Search Context

The keyword ipamorelin side effects generally concerns tolerability during human exposure.

Published clinical research has included safety monitoring.

For example, a randomized trial involving postoperative bowel-resection patients compared intravenous Ipamorelin with placebo and monitored treatment-emergent adverse events and laboratory findings.

The trial did not demonstrate its primary efficacy endpoint, and safety findings were collected in the context of controlled inpatient clinical research.

Such results cannot establish a general human safety profile for independently supplied laboratory Ipamorelin.

Important limitations include:

• Clinical formulation may differ
• Route may differ
• Dosing may differ
• Patient population may differ
• Manufacturing standards may differ
• Monitoring conditions may differ

Protide Health therefore does not claim that this research product is safe for human administration.

Ipamorelin & Gastrointestinal Research

Ghrelin-receptor signaling is also relevant to gastrointestinal motility.

Ipamorelin was investigated clinically in postoperative ileus research.

A randomized controlled trial enrolled patients after bowel resection and evaluated outcomes including tolerance of solid food and safety.

The study did not show a statistically significant improvement in the primary efficacy endpoint.

This clinical-development history demonstrates that ipamorelin has been investigated beyond simple GH-release research, but it does not establish an approved gastrointestinal indication.

Ipamorelin vs Hexarelin

Ipamorelin and Hexarelin belong to the broader growth hormone secretagogue research class but differ structurally.

Ipamorelin

• Pentapeptide
• Aib-His-D-2-Nal-D-Phe-Lys-NH₂
• Developed with emphasis on endocrine selectivity

Hexarelin

• Hexapeptide
• Structurally related to GHRP-6
• Contains 2-methyl-D-tryptophan
• Broader research history involving endocrine and extra-pituitary pathways

Neither distinction makes one peptide universally superior.

The appropriate research compound depends on the experimental question.

Ipamorelin vs GHRP-2 & GHRP-6

Early Ipamorelin development specifically compared it with GHRP-2 and GHRP-6.

All three compounds can act within the growth hormone secretagogue receptor system.

However, their endocrine response profiles differ.

In foundational preclinical experiments:

• GHRP-2 stimulated GH and also ACTH/cortisol-related responses
• GHRP-6 stimulated GH and also ACTH/cortisol-related responses
• Ipamorelin showed greater selectivity toward GH release in the tested models

These comparisons are useful for receptor-pharmacology research rather than clinical recommendations.

Research Applications

Qualified laboratories may investigate ipamorelin in systems involving:

• GHS-R1a receptor activation
• Ghrelin receptor pharmacology
• Growth hormone secretion
• Pituitary signaling
• Endocrine selectivity
• Calcium signaling
• Structure-activity relationships
• Comparative secretagogue pharmacology
• Pharmacokinetic modeling
• Analytical peptide characterization

Study conditions should be selected according to validated experimental literature and institutional protocols.

Related Protide Health Research Products

Researchers investigating structurally distinct neuropeptide signaling may review VIP 10mg for a separate receptor system involving vasoactive intestinal peptide pathways.

The Vesugen 20mg research peptide provides a chemically different short regulatory peptide model.

Researchers examining the GHRH side of endocrine signaling may review Tesamorelin as a mechanistically distinct GHRH-receptor agonist research peptide.

These compounds should not be considered interchangeable with ipamorelin peptide.

Research Format & Storage

Protide Health supplies ipamorelin as:

• Quantity: 10mg
• Form: Lyophilized powder
• Vial Size: 3mL
• Purity: 99%
• Testing: HPLC-MS verified; third-party tested
• Appearance: White to off-white
• Solubility: Soluble in water

According to the supplied specifications:

• Store at ≤6°C
• Keep sealed
• Protect from heat
• Protect from direct light
• Protect from moisture

These are laboratory storage specifications and not preparation instructions for human administration.

Research Limitations

Several limitations should be considered when interpreting ipamorelin research:

• Ipamorelin is chemically distinct from endogenous ghrelin.
• Results from GHRP-2 and GHRP-6 should not automatically be attributed to Ipamorelin.
• Human pharmacokinetic research used controlled clinical formulations.
• Historical GH-release findings do not establish therapeutic benefit.
• GH-release selectivity does not establish universal endocrine safety.
• Clinical gastrointestinal studies did not establish an approved indication.
• CJC-1295/Ipamorelin combination data should not be transferred automatically to standalone Ipamorelin.
• Animal results cannot establish equivalent human outcomes.
• Human research does not establish suitability of independently supplied research material.
• The 10mg vial amount is not a recommended human dosage.
• The Protide Health product is not an FDA-approved pharmaceutical product.

For these reasons, ipamorelin peptide is supplied strictly for qualified laboratory research.

Literature & Citation Index

Ipamorelin, the First Selective Growth Hormone Secretagogue

Journal: European Journal of Endocrinology
Year: 1998
PMID: 9849822
DOI: 10.1530/eje.0.1390552
Research Context: Ipamorelin sequence, GHRP-receptor agonism, GH release, ACTH/cortisol comparison, endocrine selectivity, and structure-activity research.

Pharmacokinetic Evaluation of Ipamorelin and Other Peptidyl Growth Hormone Secretagogues

Year: 1998
PMID: 9879640
DOI: 10.1080/004982598238976
Research Context: Ipamorelin pharmacokinetics, comparison with GHRP-2 and GHRP-6, metabolic stability, clearance, and animal absorption studies.

Pharmacokinetic-Pharmacodynamic Modeling of Ipamorelin in Human Volunteers

Journal: Pharmaceutical Research
Year: 1999
PMID: 10496658
DOI: 10.1023/A:1018955126402
Research Context: Controlled human volunteer research, Ipamorelin pharmacokinetics, GH responses, half-life, and inter-individual pharmacodynamic variability.

Prospective, Randomized, Controlled Study of Ipamorelin for Postoperative Ileus

Year: 2014
PMID: 25331030
Research Context: Controlled clinical research, postoperative gastrointestinal recovery, Ipamorelin exposure, efficacy endpoints, and safety monitoring.

Frequently Asked Questions

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide growth hormone secretagogue that acts as an agonist at the ghrelin/GHS-R1a receptor system.

What is the Ipamorelin sequence?

The sequence is:

Aib-His-D-2-Nal-D-Phe-Lys-NH₂

What is the molecular formula?

The molecular formula is:

C38H49N9O5

What is the molecular weight?

The molecular weight is approximately:

711.86 g/mol

What is the CAS number?

The CAS number is:

170851-70-4

What is the PubChem CID?

The PubChem identifier is:

CID 9831659

What does Ipamorelin peptide research investigate?

Research includes GHS-R1a signaling, ghrelin-receptor pharmacology, growth-hormone secretion, endocrine selectivity, pituitary signaling, pharmacokinetics, and secretagogue structure-activity relationships.

What is CJC 1295 Ipamorelin?

CJC 1295 ipamorelin describes a research combination involving a GHRH analogue and Ipamorelin. This product contains standalone Ipamorelin only.

Is CJC-1295 Ipamorelin the same as standalone Ipamorelin?

No. A cjc-1295 ipamorelin formulation contains more than one peptide, while this product contains only Ipamorelin.

What does CJC Ipamorelin mean?

CJC ipamorelin is shorthand for combining a CJC/GHRH analogue with Ipamorelin in research. It is not another name for pure Ipamorelin.

What is the Ipamorelin dosage?

Protide Health does not provide human ipamorelin dosage instructions. The 10mg quantity represents vial contents only.

What are Ipamorelin side effects?

Human studies have included safety monitoring, but they do not establish a universal safety profile for independently supplied research material. Protide Health does not represent this product as safe for human administration.

Is Ipamorelin selective?

Foundational research described Ipamorelin as comparatively selective for GH release relative to GHRP-2 and GHRP-6 in the experimental systems studied.

What purity does Protide Health specify?

Protide Health specifies 99% purity, with HPLC-MS verification and third-party testing.

Is Ipamorelin intended for human use?

No. It is supplied solely for endocrine, receptor-signaling, biochemical, cellular, analytical, in-vitro, and qualified preclinical research.

Laboratory Terms & Compliance

Laboratory Research Use Only

This ipamorelin product is supplied exclusively for laboratory research, growth hormone secretagogue research, receptor pharmacology, analytical testing, endocrine experimentation, in-vitro studies, cellular research, and qualified preclinical investigation.

It is not intended for human or veterinary consumption, medical use, diagnostic use, hormone treatment, bodybuilding, muscle growth, fat-loss treatment, athletic-performance enhancement, injection, nasal administration, or clinical administration.

No human dosage, injection schedule, treatment protocol, administration frequency, body-weight calculation, cycle, CJC-1295 combination protocol, or human-use preparation instructions are provided.

The purchaser is responsible for appropriate laboratory handling, storage, and use under applicable institutional, federal, state, and local requirements.

For research use only.